PMCB
What one share of Pharmacyte Biotech holds
Biological Products, (No Diagnostic Substances)
The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC,
Pharmacyte Biotech’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-07-31; the balance sheet is as of 2026-07-31.
| Sales | $0.00 |
|---|---|
| Profit | −$2.20 |
| Cash and investments | $1.66 |
| Book value | $2.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.00 | −$4.23 | — | −$2.59 | — | $4.66 |
| 2021 | $0.00 | −$2.45 | — | −$2.30 | — | $4.20 |
| 2022 | $0.00 | −$0.27 | — | −$0.27 | — | $4.34 |
| 2023 | $0.00 | −$0.22 | — | −$0.19 | — | $4.33 |
| 2024 | $0.00 | −$1.80 | — | −$0.22 | — | $3.44 |
| 2025 | $0.00 | $3.19 | — | −$0.41 | — | $7.64 |
| 2026 | $0.00 | −$2.77 | — | −$0.61 | — | $3.10 |